Latest News and Press Releases
Want to stay updated on the latest news?
-
22 June 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) ADR Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company developing a pipeline of...
-
- Traitement potentiel majeur pour de la douleur aiguë de la cystite interstitielle/syndrome douloureux de la vessie (CI/SDV). - Marché global avec une population de patients adressable d'au moins...
-
Potential first-line treatment for interstitial cystitis/bladder pain syndrome (IC/BPS)Global opportunity with a patient population of at least 6 million in the U.S. alone1 Liège, Belgium – 22 June...
-
20 June 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Appeal of Delisting Determination Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company...
-
15 June 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Receipt of NASDAQ Delisting DeterminationPlans to Appeal Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage...
-
New York, June 05, 2023 (GLOBE NEWSWIRE) -- Capital Markets Gateway LLC (CMG), a fintech company defining the future of equity capital markets (ECM) issuance, is pleased to announce that it has...
-
26 May 2023 Biodexa Pharmaceuticals PLC Announces Closing of $3.32 Million Registered Direct Offering Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (NASDAQ: BDRX), a...
-
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH...
-
MINNEAPOLIS, May 22, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) today announced that, effective May 19, 2023, the Company’s independent directors approved equity awards under Nuwellis’...
-
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Posting of Annual Report & Notice of AGM Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage biopharmaceutical company...